DexCom, Inc. (DXCM) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a hold rating to a buy rating in a report issued on Wednesday morning.

DXCM has been the topic of several other research reports. Jefferies Group LLC decreased their price objective on DexCom to $91.00 and set a buy rating on the stock in a report on Tuesday, May 9th. Oppenheimer Holdings, Inc. reiterated a buy rating on shares of DexCom in a report on Wednesday, March 22nd. Canaccord Genuity reiterated a buy rating and issued a $90.00 price objective on shares of DexCom in a report on Wednesday, June 7th. Royal Bank Of Canada reiterated an outperform rating and issued a $87.00 price objective on shares of DexCom in a report on Tuesday, April 4th. Finally, B. Riley reiterated a buy rating and issued a $95.00 price objective on shares of DexCom in a report on Tuesday, May 2nd. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. DexCom currently has an average rating of Buy and a consensus price target of $90.44.

Shares of DexCom (NASDAQ:DXCM) traded up 0.80% during midday trading on Wednesday, hitting $78.96. The stock had a trading volume of 420,905 shares. DexCom has a 1-year low of $57.68 and a 1-year high of $96.38. The stock’s market cap is $6.82 billion. The firm’s 50-day moving average price is $71.34 and its 200-day moving average price is $74.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $142.30 million for the quarter, compared to the consensus estimate of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. Analysts forecast that DexCom will post ($0.70) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://sportsperspectives.com/2017/06/22/dexcom-inc-dxcm-upgraded-to-buy-at-bidaskclub.html.

In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $78.19, for a total transaction of $250,208.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $69.07, for a total value of $414,420.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,613 shares of company stock worth $4,033,532. 1.70% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in DexCom during the first quarter valued at $136,000. IFP Advisors Inc boosted its stake in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in DexCom during the first quarter valued at $164,000. Mn Services Vermogensbeheer B.V. boosted its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after buying an additional 1,900 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply